I. AMENDMENTS

Please amend claim 18 as indicated. Upon entry of the present amendment, the status of the claims will be as follows:

1 to 17. (Cancelled)

18. (Currently amended) A method of comparing protein expression in two or more populations of cells, said method comprising:

(a) contacting an array ~~of~~ comprising uncharacterized antibodies on a solid surface with a cell lysate of a first cell population, generating a first binding pattern;

(b) contacting a duplicate array ~~of~~ comprising uncharacterized antibodies on a solid surface with a cell lysate of a second cell population, generating a second binding pattern; and

(c) comparing the binding pattern of the first cell lysate with the binding pattern of the second cell lysate.

19. (Cancelled)

20. (Withdrawn) A method according to claim 18 wherein the antibodies are recombinant antibodies.

21. (Previously presented) A method according to claim 18 wherein the first cell lysate is from normal cells and the second cell lysate is from abnormal cells.

22. (Original) A method according to claim 21 wherein the abnormal cells are cancer cells.

23. (Previously presented) A method according to claim 18 wherein the first cell lysate is from normal cells in a resting state and the second cell lysate is from normal cells in a stimulated state.

24. (Previously presented) A method according to claim 18, wherein the first cell population comprises a different detectable label than the second cell population.

25 to 47. (Cancelled)

48. (Previously presented) A method according to claim 18 wherein the first and second cell lysates are from cells from a single tissue type but from different species.

49. (Previously presented) A method according to claim 18 wherein the first and second cell lysates are from cells from a single species but from different tissue types.

50. (Previously presented) A method according to claim 18 wherein the first and second cell lysates are from cells from the same tissue type at different developmental stages.

51. (Withdrawn) The method of claim 18, wherein the antibodies are multispecific antibodies.

52. (Withdrawn) The method of claim 51, wherein the multispecific antibodies are bispecific antibodies.

53. (Withdrawn) The method of claim 18, wherein the antibodies are antigen-binding antibody fragments.

54. (Withdrawn) The method of claim 53, wherein the antigen-binding antibody fragments are Fv, Fab, Fab' or F(ab')2 fragments.

55. (Previously presented) The method of claim 18, wherein the antibodies are IgG, IgM, IgE or IgA antibodies.

56. (Withdrawn) The method of claim 18, wherein the antibodies are chimeric antibodies.

57. (Withdrawn) The method of claim 18, wherein the antibodies are humanized antibodies.

58. (Withdrawn) The method of claim 18, wherein the antibodies are single chain antibodies.

59. (Withdrawn) The method of claim 18, wherein the antibodies are diabodies.

60. (Previously presented) The method of claim 18, wherein the solid surface comprises a plastic, a complex carbohydrate, an acrylic resin, nitrocellulose, or positively charged nylon.

61. (Previously presented) The method of claim 18, wherein the solid surface comprises a glass slide, a silicon wafer, or a latex bead.

62. (Previously presented) The method of claim 61, wherein the glass slides comprises aldehyde treated glass slides or nitrocellulose slides.

63. (Previously presented) The method of claim 18, wherein the solid surface comprises polycarbonate, agarose, or polyacrylamide.

64. (Previously presented) The method of claim 18, wherein at least one spot in the array of antibodies contains about 0.01 ng to 100 ng of antibody.

65 (Previously presented) The method of claim 18, wherein the antibodies have an affinity greater than about 10^{-6} M.

66. (Previously presented) The method of claim 65, wherein the antibodies have an affinity greater than about 10^{-7} M.

67. (Previously presented) The method of claim 65, wherein the antibodies have an affinity of about 10^{-8} M to 10^{-11}M.

68. (Previously presented) The method of claim 18, wherein the first cell lysate comprises an arterial endothelial cell lysate and the second cell lysate comprises a venous endothelial cell lysate.

69. (Previously presented) The method of claim 18, wherein the first cell lysate or the second cell lysate or both comprises a bacteria lysate, a parasite lysate or a virus lysate.

70. (Previously presented) The method of claim 23, wherein the normal cells are T cells.